Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 944 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal Saline as Placebo Clear all
Completed Phase 2 Interventional Results available

Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.

NCT03422159
View directory record Official record
Conditions
Sepsis, Severe, Septic Shock
Interventions
Ascorbic Acid, Thiamine, Hydrocortisone, Sodium Chloride 0.9%
Drug
Lead sponsor
Community Medical Center, Toms River, NJ
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lakewood, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

NCT02044094
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

NCT01291602
View directory record Official record
Conditions
Healthy Male and Female Japanese Volunteers
Interventions
NXL104, CAZ104, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

NCT06193031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
C16TR, Placebo, Tyvaso®
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 8, 2026, 4:23 PM EDT
Not listed Not applicable Interventional

Ultrasound-Guided Obturator Nerve Block for Ambulatory Hip Arthroscopy

NCT02346357
View directory record Official record
Conditions
Pain
Interventions
Obturator Nerve Block, Ropivacaine, Placebo Saline
Procedure · Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

NCT01575405
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation
Drug
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

NCT01352845
View directory record Official record
Conditions
Healthy
Interventions
rLP2086, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 25 Years
Enrollment
3,301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
35
States / cities
Mobile, Alabama • Mesa, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

NCT04600089
View directory record Official record
Conditions
Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm
Interventions
Saline, Ketamine
Drug
Lead sponsor
Eric Johnson
Other
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 8, 2026, 4:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

NCT02037555
View directory record Official record
Conditions
Cardiac Surgery, Cardiopulmonary Bypass
Interventions
AT-III (Human), Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
41
States / cities
Orange, California • San Francisco, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00156910
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 8, 2026, 4:23 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?

NCT02939742
View directory record Official record
Conditions
PPROM, Respiratory Distress Syndrome in Premature Infants
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 8, 2026, 4:23 PM EDT
Terminated Not applicable Interventional

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

NCT02548494
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 8, 2026, 4:23 PM EDT
Terminated Phase 4 Interventional Results available

Sputum-derived Cellular Targets After Xolair (Omalizumab)

NCT02658877
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

NCT02742103
View directory record Official record
Conditions
Acute Myocardial Infarction, Moderate Renal Impairment
Interventions
CSL_112, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

NCT05996835
View directory record Official record
Conditions
Acute Kidney Injury Due to Sepsis
Interventions
TIN816 70 mg lyophilisate powder, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 8, 2026, 4:23 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244
View directory record Official record
Conditions
Healthy
Interventions
Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix
Biological
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 49 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
120
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Not applicable Interventional Results available

The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery

NCT01782898
View directory record Official record
Conditions
Pain
Interventions
Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min, Placebo Comparator: .9 normal saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 8, 2026, 4:23 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults

NCT05721287
View directory record Official record
Conditions
Pain, Acute Pain
Interventions
SBS-1000, Placebo
Drug
Lead sponsor
Sparian Biosciences, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 8, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional

A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo

NCT01771471
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
NuQu, Placebo
Biological · Other
Lead sponsor
ISTO Technologies, Inc.
Industry
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 8, 2026, 4:23 PM EDT
Recruiting Phase 3 Interventional

PRP in ACLR to Prevent PTOA

NCT05412381
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Post-traumatic Osteoarthritis, PRP
Interventions
platelet rich plasma (PRP) injection, placebo saline injection
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
14 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

NCT04678830
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebos, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Aventura, Florida • Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 8, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

NCT02669121
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NoV Placebo-matching Saline, NoV GI.1/GII.4 Bivalent VLP Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,748 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Great Lakes, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 8, 2026, 4:23 PM EDT